Brief: Veru Announces FDA Clearance Of IND Application To Initiate Phase 2B Clinical Trial with Enobosarm

Veru

06/02/2024 14:25

Feb 6 (Reuters) - Veru Inc  VERU.O :
    * VERU ANNOUNCES FDA CLEARANCE OF IND APPLICATION TO
INITIATE
PHASE 2B CLINICAL TRIAL WITH ENOBOSARM TO TREAT MUSCLE LOSS
ASSOCIATED WITH WEIGHT LOSS DRUGS
    * VERU INC - PHASE 2B CLINICAL TRIAL IS EXPECTED TO INITIATE
BY
APRIL 2024
    * VERU INC - PHASE 2B CLINICAL TRIAL FINAL TOPLINE RESULTS
ARE
ANTICIPATED BY YEAR-END
    * VERU INC - RESULTS OF SEPARATE PHASE 2B OPEN LABEL
EXTENSION
CLINICAL STUDY IS EXPECTED IN CALENDAR Q2 2025
    * VERU INC -  CLEARANCE OF IND WILL ALLOW US TO EVALUATE
ENOBOSARM
AS A COMBINATION TREATMENT WITH GLP-1 DRUGS TO PREVENT LOSS OF
MUSCLE

Source text for Eikon:  ID:nGNX8PD4ZF 
Further company coverage:  VERU.O 

 ((Reuters.Briefs@thomsonreuters.com;))